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ABSTRACT
Doxorubicin, a widely used chemotherapeutic drug, has several potential high-
risk side effects including cardiomyopathy. Furthermore, cellular resistance to this 
drug develops with time. By using liposomes as carrier vesicles both the side effects 
and drug resistance might be avoided. In this study we have investigated the cytotoxic 
effect of doxorubicin encapsulated in liposomes with and without ceramides containing 
6 or 12 carbon atoms in the N-amidated fatty acyl chains. The short-chain ceramide 
species were included in the liposomal compositions due to their pro-apoptotic 
properties, which might cause a synergistic anticancer effect. We demonstrate that 
the ceramide species enhance the liposomal doxorubicin toxicity in a cell-specific 
manner. The C6-ceramide effect is most pronounced in cervical cancer cells (HeLa) 
and colon cancer cells (HCT116), whereas the C12-ceramide effect is strongest in 
breast cancer cells (MDA-MB-231). Moreover, the study reveals the importance of 
investigating cell toxicity at several time points and in different cell-lines, to assess 
drug-and formulation-induced cytotoxic effects in vitro. Furthermore, our data show 
that the cytotoxicity obtained with the nanocarriers in vitro, does not necessarily 
reflect their ability to inhibit tumor growth in vivo. We speculate that the larger effect 
of Caelyx® than our liposomes in vivo is due to a greater in vivo stability of Caelyx®.
INTRODUCTION
Chemotherapy has improved the prognosis of a 
number of different cancer diagnoses during the last 
decades, but unwanted drug effects on healthy tissue 
remain a major problem. A challenge is the heterogenic 
nature of the tumor and the microenvironment, as well as 
the inherent or acquired drug resistance of tumor cells, 
in addition to the adverse effects seen on normal tissue. 
An emerging approach to overcome these challenges 
is to use drug-loaded nanocarriers that may maximize 
tumor growth inhibition, reduce the systemic toxicity, and 
overcome drug resistance.
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Liposomes are suitable drug carrier systems for 
therapeutic applications in cancer treatment, and able 
to incorporate drugs with different physicochemical 
properties [1, 2]. The properties of liposomes depend on 
the lipid composition, as it will affect the biodistribution, 
surface charge, drug permeability and drug release, as 
well as clearance of the liposomal drug from the body. 
Thus, liposomes may protect the drug from enzymatic 
degradation, improve the drug pharmacokinetics, and 
tissue distribution, and provide a sustained or controlled 
release of therapeutic agents at appropriate sites [3, 4].
One of the most successful liposome-encapsulated 
drugs is doxorubicin (DOX), available as the marketed 
(PEGylated liposomal) product Doxil®/Caelyx® [5, 
6], approved by FDA in 1995. Its prolonged circulation 
time and gradual release of DOX led to increased 
efficacy and reduced cardiomyopathy. However, higher 
susceptibility towards hand-and-foot disease (palmar 
plantar erythrodysthesia) in patients treated with Doxil®/
Caelyx® [7] drives the investigations towards improved 
formulations of PEGylated liposomal DOX.
Incorporation of ceramide into the liposomal lipid 
bilayer could improve the therapeutic effect of liposomes 
[8]. Ceramide, a key molecule in sphingolipid metabolism, 
is composed of a sphingosine base and an amide-linked 
acyl chain varying in length; the endogenous species most 
commonly contain fatty acyl groups with 16 to 24 carbon 
atoms. It is a bioactive sphingolipid linked to induction of 
senescence, growth inhibition, and death in cancer cells 
[9, 10]. The PI3K-PKB/Akt signalling cascade determines 
much of a cell’s growth potential, and is strongly linked 
to tumorigenesis. This pathway is considered the main 
route for cellular effects of ceramide, and downstream 
targets include several stress-activated protein kinases 
[11]. Additionally, ceramide potently inhibits angiogenesis 
through IFN-gamma activation [12]. Cellular membranes 
with different ceramide species, with varying hydrocarbon 
chain lengths, also show dissimilar properties in terms of 
stability and rigidity [13-15]. This suggests that ceramide 
modulation of liposomal membranes would impact 
intracellular transport of the liposomes [16]. The free 
form of the short-chain ceramide C6 has been shown to 
be an effective mediator of caspase-dependent cell death, 
but is surpassed by a similar dose of liposomes containing 
this ceramide species [17], due to low solubility in cell 
medium and less efficient cellular uptake of the free 
ceramide C6. A change in liposomal structure could also 
be beneficiary to increase cellular permeability [18].
DOX is an anthracycline antibiotic with 
antineoplastic activity. The drug exerts its cytotoxicityby 
intercalating with DNA base pairs, as well as interacting 
with several molecular targets such as DNA topoisomerase 
II to produce a range of effects [19]. Importantly, it 
is also reported to increase the intracellular ceramide 
level, further enhancing the apoptotic potential [20]. The 
resistance to DOX seen in several cancer types is partly 
attributed to the induced activity of glucosylceramide 
synthase (GCS) [15, 21, 22]. GCS glucosylates ceramide 
and thereby counteracts the pro-apoptotic effects of 
ceramide. By adding exogenous ceramides concomitantly 
with doxorubicin one might reduce GCS-mediated 
depletion of pro-apoptotic ceramide [23].
The size of liposomes and other nanoparticles has a 
direct effect on their circulation time and biodistribution 
following intravenous injection. Particles with a diameter 
below 200 nm are taken up into liver and spleen (the 
reticuloendothelial system) more slowly than larger 
particles, and thus relatively more of the injected dose is 
being trapped in tumors due to the enhanced permeability 
and retention (EPR) effect [24]. In the present study we 
have investigated the effect of ceramide with different 
chain lengths (C6 and C12) in PEGylated liposomes with 
encapsulated DOX. The effect of such liposomes was 
studied in various cancer cell lines and in a mice breast 




The size and polydispersity index (PDI) of our 
liposomal formulations (Figure 1A) were compared to 
the average size and PDI of the marketed PEGylated 
liposomal product Caelyx®. All our liposomal 
formulations exhibited larger PDI than our measurements 
of Caelyx® (Supplementary Table 1). However, the 
PDI of our liposomal formulations was comparable to 
that reported in other studies with ceramide-containing 
liposomes [25]. Inclusion of ceramide equimolar to 
doxorubicin into liposomes did not affect their physical 
characteristics. Figure 1B displays the retention of DOX 
in the different liposome formulations, i.e. DOX-Lip, 
DOX-Lip-C6, DOX-Lip-C12 and Caelyx®, after being 
dispersed in two different solutes; 5% (w/v) sucrose 
solution (pH 5.0), and cell growth medium (DMEM+FCS, 
pH 7.4), respectively. The amount of DOX released from 
the liposomes at various time points was determined by 
HPLC. The stability of all liposomal formulations was 
higher in storage solution than in growth medium. A 
higher DOX-release was observed from the investigated 
formulations than for Caelyx® when these formulations 
were incubated in the medium (Figure 1B). The DOX-
containing liposomes exhibited a half-life of 40-55 h for 
the release of DOX, whereas a small increase in half-life, 
although not significant, was observed for the ceramide-
containing liposomes.
The characteristics of the liposomal formulation 
in cell cultures were also determined. HeLa cells were 
incubated with the different DOX-containing liposomes 
for 24 h. To separate encapsulated from released DOX, 
mild lysis conditions (0.1% (v/v) Triton X-100) were used 
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Figure 1: Description of liposomal formulations used in the study. (A) Illustrations of liposomes used. PL= phospholipids, 
PEG = polyethylene glycol, DOPE = dioleoylphosphatidyl-ethanolamine, DSPC = distearoyl-sn-glycero-3-phosphocholine, DSPE = 
1,2-distearoylphosphatidyl-ethanolamine. (B) Liposomal stability in solution. DOX-containing liposomes (1 mM) were incubated in 
stock solution (5% (w/v) sucrose solution pH 5.0 or in growth medium (DMEM with 10% (v/v) FCS, pH 7.4 for 24, 48 or 72 h. The 
liposomes were filtered and DOX was quantified to determine the percent of DOX retained in liposomes. The values show average of three 
experiments with standard deviations. (C) Effect of ceramide on doxorubicin release from liposomes. HeLa cells were incubated with 
various concentrations (30 – 1000 nM) of four different DOX-loaded liposomes and Free-DOX. After 24 h the cell medium was removed, 
cells washed and lysed using 0.1% (v/v) Triton-X100. DOX still encapsulated in liposomes was separated from free/released DOX by solid 
phase extraction and quantified. The data show the percent of DOX being encapsulated in liposomes or free. Mean values obtained by 
analyzing 3 replicates are shown.
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to lyse the cells, but not the liposomes (Supplementary 
Figure 1). The lysate was separated from intact liposomes 
on a solid phase extraction C18 column to distinguish 
between liposomal and unbound DOX, and the DOX 
content in each fraction was measured relative to the 
same concentration of untreated vesicles/compound after 
extraction with 1.5% (v/v) Triton X-100 (Figure 1C). The 
resulting data show that release of DOX is concentration-
dependent and that for all liposomal formulations, beside 
Caelyx®, only between 5 and 20% is extractable after 1 
h (Supplementary Figure 2), which increases to 45-60% 
after 3 h, and reaches 70-80% after 24 h. For Caelyx® 
only a very minor fraction of the total DOX is not 
contained in the liposomal form even after 24 h.
Liposomal ceramides induce higher toxicity for 
DOX in cells
The cytotoxicities obtained with the different 
preparations measured as cell proliferation with [3H]
thymidine incorporation, are shown in Figure 2 and the 
IC50-values are shown in Supplementary Table 2. The 
results indicate a significantly higher toxicity of ceramide 
C6-containing liposomes loaded with doxorubicin (DOX-
Figure 2: Dose-dependent effect of liposomal doxorubicin on cell proliferation. (A-C) Three different cell lines were incubated 
for 24 h with various concentrations of liposomal DOX (10-3000 nM) followed by measuring incorporation of [3H]thymidine. Free-DOX, 
empty liposomes with same lipid concentration or no treatment was used for comparison. A) HeLa, B) HCT116, C) MDA-MB-231. (D-F) 
Time-dependent effect of liposomal DOX on the cell proliferation. HeLa cells incubated with increasing liposomal DOX-concentrations 
(30, 300 and 3000 nM) or empty liposomes with same lipid concentration were incubated for up to 72 h and the cell proliferation was 
determined by measuring the incorporation of [3H]thymidine (Free-DOX used for comparison) at various time points (8 - 16 - 24 - 48 - 72 
h). D) HeLa 30 nM, E) HeLa 300 nM, F) HeLa 3000 nM. The data show the mean values from at least three independent experiments and 
standard deviations. The total lipid concentration of the formulations is displayed on the secondary x-axis in A-C.
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Lip-C6), as compared to free doxorubicin (Free-DOX) in 
HeLa (Figure 2A) and HCT116 (Figure 2B) cells after 24h 
of incubation. The effect is especially prominent at lower 
concentrations (below 100 nM). In contrast, the breast 
cancer cell line MDA-MB-231 (Figure 2C) exhibited a 
higher sensitivity towards DOX-Lip-C12 liposomes than 
DOX-Lip-C6, and was, in general, more resistant to DOX 
than the other cell lines. Ceramide liposomes without 
DOX and Caelyx® were much less toxic to these cells 
after 24 h incubation, although some minor toxic effects 
were observed at the highest concentration of 3 μM.
Figure 2D-2F displays the time/concentration-
dependent relationship between different formulations 
during 72 h incubation of HeLa cells, in particular 
revealing the delayed effect of Caelyx®. These results 
demonstrate the sustained release of DOX from liposomes 
when compared to Free-DOX (see also Supplementary 
Figure 3A). The delayed toxic effect was most prominent 
at low concentrations (Figure 2D; 30 nM), but it is evident 
for Caelyx® also at higher concentrations. In summary, 
it appears that different ceramide chain lengths (C6 for 
HCT116 and HeLa; C12 for MDA-MB-231) exhibit 
synergistic cell toxicity with DOX; the synergy being 
most prominent at low dosage, and thus the combined 
ceramide and DOX treatment might allow use of lower 
concentrations of DOX in cancer treatment, retaining the 
same efficacy.
To assess whether ceramide alone influences 
cell survival more efficiently over time, different 
concentrations of empty liposomes were tested in the 
same three cell lines using the MTT assay, since this 
viability assay addresses the integrity of the mitochondrial 
metabolic activity – a known target for ceramide toxicity 
[26, 27]. High concentrations of ceramide C6 (>3 μM) 
were highly toxic to HeLa (Figure 3A) and HCT116 cells 
(Figure 3B) after 72 h, and in HeLa cells the toxicity was 
already prominent after 24 h (Supplementary Figure 3B). 
The MDA-MB-231 cells, tested in the same assay (Figure 
3C), exhibited higher sensitivity towards ceramide C12 
than the other cell lines, which remain mostly unaffected 
by the exposure to empty C12 liposomes.
The IC50-values observed for DOX-treatments 
in MDA-MB-231 cells for the MTT assay compared 
to the other two cell lines are comparable, in contrast 
to the difference seen for cell proliferation measured 
by [3H]thymidine incorporation between the cell types 
(summarized in Supplementary Table 2). This reflects 
either that the MDA-MB-231 cell line has a more robust 
cell division, or a larger dependency on mitochondrial 
activity, or both. Another option is the difference in plasma 
membrane composition among the cell lines.
Higher amounts of ceramide affect DOX toxicity 
in a cell-dependent manner
To investigate the relationship between the 
cytotoxicity of ceramide and DOX, cells were treated 
with DOX-loaded liposomes giving a DOX and ceramide 
Figure 3: Dose-dependent effect of liposomal doxorubicin on cell viability. Cells were incubated for 72 h with various 
concentrations of DOX-containing (30 - 3000 nM DOX) liposomes and compared to Free-DOX and empty liposomes with the same lipid 
concentration. Cell viability was determined by using the MTT assay. (A) HeLa, (B) HCT116, (C) MDA-MB-231. The data show the mean 
values from at least three independent experiments and standard deviations. The total lipid concentration of the formulations is displayed 
on the secondary x-axis.
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concentration between 0.03 and 1 μM. Half of the samples 
were further treated with increased amounts of ceramide 
by adding Empty-Lip-C6 to cells treated DOX-Lip-C6, 
or Empty-Lip-C12 to cells treated with DOX-Lip-C12 
equivalent to an additional 1 μM ceramide. The same 
additions of Empty-Lip-C6 to Free-DOX and of Empty-
Lip-C12 to Caelyx® are shown for comparison. The 
cytotoxicity was determined by the MTT cell viability 
test after 72 h (Figure 4A-4B). Ceramide addition was 
most potent when combined with Free-DOX, but also 
significantly increased the toxicity of DOX-Lip-C6 at 
lower concentrations in the HCT116 cell line (Figure 4A). 
In contrast, the MDA-MB-231 cells were more sensitive 
to additional amounts of ceramide C12 (Figure 4B). The 
toxic effect of Caelyx® was also slightly affected by 
addition of C12 ceramide, which has a protective role in 
HCT116, but sensitizing in MDA-MB-231. Similar effects 
were observed when adding Empty-Lip-C12 together with 
Free-DOX or Empty-Lip-C6 together with Caelyx® (data 
not shown).
Influence of ceramide in liposomes on kinetics of 
DOX-release
In order to study in more detail the kinetics of the 
intoxication with the liposome formulations, HeLa cells 
were incubated for 1, 3 and 24 h with the DOX containing 
liposomes (DOX-Lip-C6, DOX-Lip-C-12, DOX-Lip and 
Caelyx®) and Free-DOX. All cells were grown for 24 h, 
but for 1 and 3 h incubation samples, cells were washed 
(twice) and medium changed after 1 and 3 h, respectively, 
prior to continued incubation for a total of 24 h. At the end 
of the incubation, the cell proliferation was determined 
by the [3H]thymidine incorporation assay (Figure 5). 
A slightly more prominent cell toxicity was observed 
for the DOX-Lip-C6 treated cells, as compared to cells 
Figure 4: Dose-dependent effect of increased ceramide addition to liposomal doxorubicin on cell viability. (A) HCT116, 
(B) MDA-MB-231. Cells were incubated with various concentrations (30 nM - 1000 nM) of DOX-containing liposomes for 72 h. One part 
of the samples had an additional 1 μM of ceramide of same type of ceramide-liposomes without DOX added. Empty-Lip-C6 were added 
to DOX-Lip-C6 and Free-DOX, and Empty-Lip-C12 were added to DOX-Lip-C12 and Caelyx® and incubated for 72 h. The comparison 
was made between no addition (blue bars) and additional ceramide-containing liposomes (red bars). The cells’ viability was determined by 
using the MTT assay. The data show the mean values from three independent experiments and standard deviations. *p<0.05.
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treated with ceramide-free formulations (DOX-Lip) 
after 3 h (p>0.05), but in general only minor differences 
were observed. This lack of impact of ceramide on the 
kinetics of drug release was also seen when quantifying 
DOX retained and released from liposomes given to cells 
(Supplementary Figure 2.).
Ceramide and DOX affect different cell death 
mechanisms
The relationship between ceramide and DOX in 
terms of cell death signaling was assessed by mixing 
increasing amounts of drug and liposomes with the 
pan-caspase inhibitor zVADfmk and incubating for 24 
h (Figure 6A). The inhibitor partly rescued cells from 
Free-DOX induced toxicity, but failed to inhibit cell death 
induced by empty or DOX-loaded ceramide-containing 
liposomes. DOX-C6-Lip induced PARP cleavage, a 
hallmark of apoptotic cell death [28], at 3 μM, similarly to 
Free-DOX, but C6-ceramide alone does so only marginally 
(Figure 6B). Low concentrations of DOX induced 
phosphorylation of AKT, whereas this effect was less 
pronounced at elevated DOX concentrations. In contrast, 
ceramide does not appear to induce phosphorylation of 
AKT at these concentrations (10-30 μM), supporting 
previous findings seen with C6-nanoliposomes in vitro 
[29]. The cytotoxic effect of ceramide could potentially be 
mediated through AMPK since Empty-C6-Lip enhanced 
its phosphorylation.
Ceramide does not enhance the effect of DOX on 
tumor growth in a mouse model
The effect of DOX-containing liposomes on 
tumor growth was studied by intravenous injection of a 
liposomal formulation corresponding to a DOX dose of 8 
Figure 5: Influence of ceramide in liposomes on kinetics of DOX effect on cell proliferation. (A) Free-DOX, (B) DOX-
Lip-C6, (C) DOX-Lip-C12, (D) Caelyx®, (E) DOX-Lip. HeLa cells were incubated with various concentrations (30 – 1000 nM) of four 
different DOX-loaded liposomes and Free-DOX. After 1 and 3 h, one third of the cells were washed twice, fresh medium was added and the 
incubation extended. After a total of 24 h incubation the cell proliferation were compared with that of continuously treated cells. The data 
show the mean values from three independent experiments and standard deviations.
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mg/kg to mice bearing MAS98.12 patient-derived breast 
cancer xenografts (Figure 7). Two weeks after treatment 
all DOX-additions reduced the tumor volume compared to 
that obtained with the empty liposomes (negative control). 
Although not statistically significant, ceramide containing 
liposomes seem to have a slightly better effect on tumor 
growth than Free-DOX, and Caelyx® seems to have the 
best effect (Figure 7). The tumor growth was equal for all 
the empty liposome treatments (Empty-Lip-C6, Empty-
Lip-C12 and Empty-Lip), indicating no effect of ceramide 
alone, regardless of chain length (C6 or C12). Little 
difference was observed for systemic toxicity between 
the different DOX-containing liposomes, albeit Free-
DOX was more toxic than DOX-Lip-C6 and Caelyx® 
(Supplementary Figure 4).
DISCUSSION
In vitro: kinetics and mechanism
A main finding in the present study is that when 
studying the effect of ceramide inclusion into PEGylated 
Figure 6: Effects of ceramide and doxorubicin on cell death signaling. (A) HeLa cells were incubated with various 
concentrations (1-30 μM) of DOX-loaded liposomes and Free-DOX. Pan-caspase inhibitor zVADfmk (10 or 30 μM) was added to address 
the effect of caspase-activity on cell viability measured by the MTT assay after 24 h. Bar graphs show mean values from three independent 
experiments and standard deviations. (B) Immunoblotting of HeLa cells were performed to investigate influence of ceramide and DOX 
on cellular signaling pathways. HeLa cells treated with either Free-DOX (0.1 - 10 μM), Empty-Lip-C6 (0.3 - 30 μM) or DOX-Lip-C6 
(0.3 – 30 μM) were lysed, the lysates separated on SDS-PAGE and immunoblotted against PARP, phosphorylated (Ser473) AKT, GAPDH, 
phosphorylated (Thr172) AMPK and gamma-tubulin in duplicate. Untreated cells, cells treated with Empty-Lip or Staurosporin (1 μM) 
were used as controls.
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liposomes containing DOX, the toxicity is dependent upon 
the cell line, the time of incubation and the test assay used. 
After 24 h incubation ceramide C6 was more effective 
than ceramide C12 in increasing toxicity to HeLa and 
HCT116 cells, whereas ceramide C12 was more effective 
for MDA-MB-231 cells. The MDA-MB-231 cells were 
less sensitive to the DOX-containing preparations than the 
two other cell lines after 24 h of incubation as measured 
with [3H]thymidine incorporation. By increasing the 
incubation time to 72 h the HeLa cells became much 
more sensitive to all DOX-containing preparations 
with Free-DOX being the most toxic substance tested 
(Supplementary Figure 3A/data not shown). When 
compared to Caelyx®, the ceramide-containing liposomes 
show higher toxicity at the same DOX-concentrations at 
incubation time up to 48 h, whereas only minor differences 
were observed after 72 h, indicating a slower release 
of DOX from Caelyx®, which has been promoted as a 
‘model’ PEGylated liposomal DOX [30]. However, the 
prolonged circulation time that in most cases is regarded 
to be favorable, could be the cause of the adverse effects 
seen for this treatment [31]. We observed an increased 
cellular toxicity in MDA-MB-231 cells when combining 
C12 ceramide with Caelyx® (Figure 4) suggesting that 
inclusion of ceramide in liposomes may be beneficiary. 
Another phenomenon is the moderate toxic effect of 
Caelyx® observed to a similar extent in all cell lines 
when using the MTT assay, indicating that cell energy 
metabolism is merely slightly disturbed. This is in contrast 
to the strongly reduced cell proliferation after 72h with 
Caelyx® in HeLa cells (Figure 2F).
There are several reasons to investigate the potential 
for using ceramide in combinational drug therapy. For 
example, pretreatment with ceramide has been shown to 
resensitize drug-resistant cells to the primary treatment 
modality comprising DOX- or paclitaxel-loaded 
nanoparticles [20, 32]. Also, it is known that the synthesis 
of glycosphingolipids from ceramide is increased in 
cancer cells [33] thereby counteracting the pro-apoptotic 
effect of ceramide. By overwhelming the enzymatic 
processing (saturating GCS) with additional ceramide a 
more consistent pro-apoptotic signaling may be sustained. 
However, efficient delivery of drug combinations in the 
clinical setting depends on a number of factors. Thus, 
the ability to synchronize the release of the individual 
therapeutic agents applied in combination, not only allows 
for simultaneous tumor accumulation, but might also 
induce a synergistic effect at the intracellular level that 
could prove to be advantageous.
Assessing the usefulness of adding exogenous 
ceramide to cells offers some challenges regarding the 
intracellular metabolism. There are several downstream 
products of ceramide that have vastly different intracellular 
effects, such as glycosphingolipids (e.g. gangliosides 
and cerebrosides), sphingomyelin and sphingosines. 
Several studies have investigated ceramide C6 as an 
active ingredient in liposomes, but no studies have 
compared the effect of ceramide C6 with longer chain-
length ceramide species, and as discussed above ceramide 
C6 and C12 gave different effects on the three cell lines 
studied. This observation could be explained by cell line 
(or tissue) specific expression of key enzymes in the 
Figure 7: Effect of ceramide liposomes on tumor growth in mice bearing MAS98. 12 breast cancer xenografts. The tumor 
volumes were measured from day 22, i.e. one day prior to injection day (arrow mark) and up to day 47, i.e. 24 days after intravenous 
injection of DOX-containing liposomes or Free-DOX (8 mg/kg DOX) or a similar amount of empty liposomes. Tumor volumes are shown 
as relative to the tumor volumes at start of treatment. Data show mean values and standard deviations (n = 7-11 tumors).
Oncotarget76930www.impactjournals.com/oncotarget
glycosphingolipid metabolism, or differences in the lipid 
composition of the cellular membranes [23]. Moreover, 
ceramide C12 should be expected to give more stable 
liposomes [15] and perhaps a slower release of DOX than 
those containing ceramide C6 [34], a property that might 
be important to kill slow-growing cells. In agreement with 
this idea ceramide C12 is more efficient than ceramide C6 
on the slow growing MDA-MB-231 cells (doubling time 
38 h compared to approximately 24 h for the two other cell 
lines). Since previous studies with C6-liposomes in these 
cells show effects in combination with sorafenib [29] or 
taximofen [35], this result could suggest an even greater 
effect with C12-liposomes for same or similar drugs in 
triple negative breast cancer cells.
Our in vitro cell toxicity studies revealed that 
the selected assays resulted in different readout of the 
cellular toxicity. The cell proliferation assay, measuring 
incorporation of [3H]thymidine, did not reveal any 
significant effect of ceramide alone after 24 h (Figure 2), 
while such an effect was evident when using the MTT cell 
viability assay (Supplementary Figure 3B). Testing the 
toxic effects on cells after various incubation times may 
reveal important differences in the cellular response, such 
as the delay here reported for Caelyx® toxicity. Thus, to 
understand the mechanisms of added drugs, and especially 
when trying combinatorial approaches, different types of 
in vitro assays are important.
In vivo studies
The different liposome preparations were 
intravenously injected in mice with breast cancer 
xenografts (MAS98.12) to study the effect on tumor 
growth. These studies showed large effects on the tumor 
growth of all DOX-containing formulations, but did not 
show any significant difference between Free-DOX and 
CER-Lip-DOX. This may be due to insufficient ceramide 
concentration in the liposomes, since our data do not reveal 
any effect of ceramide alone, in contrast to previous studies 
where 20-30x higher final ceramide concentrations were 
used [36-38]. Fonseca et al. suggest that the ratio between 
ceramide and DOX influences the cytotoxicity of ceramide 
liposomes [25]. In contrast to their findings, we cannot see 
any increased toxic effect of a 1:1 ratio in vivo, but our data 
are in agreement with their suggestion of a more efficient 
ratio of 2 mole ceramide per 1 mole doxorubicin in the 
liposomal formulation in vitro. Increasing the ratio to 10:1 
(CER:DOX) did not give an additional effect (Figure 4).
We speculate that the larger effect in vivo of 
Caelyx® compared to our liposomes is due to a greater 
in vivo stability of Caelyx®. If true, different stabilities 
may be due to the presence of ceramide in our liposomes 
or the presence of cholesterol in Caelyx®. Although, we 
did not observe an increased therapeutic effect by adding 
ceramide to our liposomes, we can of course not exclude 
the possibility that ceramide might improve the effect in 
another tumor model, e.g. with a different growth rate.
MATERIALS AND METHODS
Materials
Doxorubicin (DOX) was purchased from Eurasia’s 
Chemicals and API (Mumbai, India). All lipids; 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] ammonium 
salt (DSPE-PEG2000), 1,2-dioleyl-sn-glycero-3-
phosphoethanolamine (DOPE), N-hexanoyl-D-erythro-
sphingosine (Ceramide C6), and N-lauroyl-D-erythro-
sphingosine (Ceramide C12), were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). DMEM 
and RPMI 1640 AQmedium, dimethyl sulfoxide 
(DMSO), ammonium sulfate, sodium chloride 
(Fluka, Germany), sucrose, Triton X-100, potassium 
hydroxide, trichloroacetic acid (TCA), formic acid 
eluent additive for LC-MS (Fluka), acetonitrile LC-
MS CHROMOSOLV®, zvAD-FMK, 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT; cat#M5655), and penicillin/streptomycin (Pen/
Strep P4333) were obtained from Sigma-Aldrich 
Chemie (Germany). [3H]thymidine and Emulsifier Safe 
scintillation fluid were obtained from Perkin Elmer 
(USA). Milli-Q water was freshly prepared from the 
Millipore Milli-Q Biocell water purification system. 
Caelyx® was bought from Janssen-Cilag International 
(Belgium). Adrianamycin was purchased from Pfizer, 
Switzerland. Antibodies against phosphorylated (Thr172) 
AMPK, phosphorylated (Ser473) AKT and PARP were 
purchased from Cell Signaling Technologies (USA), 
anti- GAPDH from Abcam and anti-gamma-tubulin were 
obtained from Sigma.
Preparation of liposomes
Liposomes containing DOX and corresponding 
empty liposomes (Figure 1A) were prepared by the 
method originally reported by Haran et al. [39]. The lipids 
were dissolved in methanol/chloroform solution (1:1, v/v) 
and the solvents evaporated on Büchi rotavapor R-124 
(Büchi Labortechnik, Flawil, Switzerland) for at least 2 
h at 50 mmHg and 65 °C. Lipid films were hydrated by 
110 mM ammonium sulfate at 65 °C in a water bath for 
1 h. Liposomal suspensions were stored refrigerated at 5 
°C overnight and sonicated to desired vesicle size using 
Ultrasonic processor VC (750 W; Sonics and Materials, 
Newton, CT, USA). The sonication time (2 min interval) 
was dependent on the lipid composition and varied from 
5 x 2 min to 10 x 2 min. The samples were left to cool for 
5 min after each sonication cycle. To form an ammonium 
sulfate gradient, dialysis was performed for 6 h against 
10% (w/v) sucrose [39]. A solution of DOX (22 mg/
mL) was added to liposomal suspensions and the loading 
performed at 65 °C for 1 h. The loading was terminated by 
the removal of unentrapped DOX by dialysis using tubing 
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with cut off of 12–14 000 Da (Medicell International Ltd., 
London, UK).
Liposome size and size distributions
The size distributions were determined by a 
photon correlation spectroscopy (Submicron particle 
sizer model 370, Nicomp, Santa Barbara, CA, USA) 
as reported previously [40]. The particle intensity was 
adjusted to approximately 250-350 kHz; the analyses 
were run in a vesicle mode and expressed as intensity-
weight distribution. Three parallels (with a run time of 10 
min for each parallel) were determined for each sample 
measurement.
Liposome DOX entrapment efficiency
The unentrapped DOX was separated from DOX-
containing liposomes by dialysis, and the DOX content 
subsequently analyzed by HPLC (Supplementary 
Table 1). The proportion of DOX present inside the 
liposome (encapsulated drug) relative to the total amount 
of drug added to the liposome dispersion was calculated 
from the amount of DOX present in the liposome samples 
prior to and after dialysis.
DOX HPLC-quantification
DOX was quantified using a Waters HPLC system, 
equipped with a Waters e2795 separations module, a 
Waters 2489 UV/Visible detector and a C-18 column: 
XSELECT CSH column XP, 2.5 μm 3.0x75 mm (Waters, 
Dublin, Ireland). Detection wavelength was 254 nm, and 
the injection volume was 10 μL. The flow rate was set to 
0.5 mL/min and the temperature was set to 25 °C. Two 
mobile phases were applied for gradient flow condition. 
Mobile phase A was Milli-Q water with 0.1% (v/v) formic 
acid and Mobile phase B was acetonitrile with 0.1% (v/v) 
formic acid. The mixing ratio of Mobile phase A and 
Mobile phase B was changed linearly from 95:5 to 5:95 
(v/v) during 10 min, and with succeeding equilibration 
sequence of 5 min. Liposome samples and standard 
samples were prepared in triplicate in Mobile phase A 
and Triton X-100 95:5 (v/v). Each DOX standard solution 
(concentration range 5-100 μg/mL) was injected three 
times into the HPLC (linear standard curves R2 value was 
0.9997). DOX retention time (RT) was 4.8 min, whereas 
the Triton X-100 top had a RT of approximately 10.0 min.
Cell lines
Three commonly used cell lines, routinely tested for 
mycoplasma, were used in this study. The MDA-MB-231 
triple negative breast cancer cell line was cultured in RPMI 
1640, while HeLa cervical cancer cells and HCT116 colon 
carcinoma cells were cultured in DMEM. All the cell lines 
were obtained from ATCC. Both media were supplemented 
with 10% (v/v) heat-inactivated fetal calf serum (FCS), 
100 U/mL penicillin and 100 μg/mL streptomycin, and 
maintained at 37 °C in a 5% CO2 atmospheric incubator. 
The experiments started 24 h after cell seeding, to enable 
attachment of the adherent cells before the corresponding 
incubation. HeLa and HCT116 cells were seeded to a final 
concentration of 5000 cells per well in 96-well plates, 
whereas 8000 cells were seeded for MDA-MB-231 due to 
a reduced proliferation of these cells. The corresponding 
number of cells applied in the 24-well plate format was 10 
times higher than applied in the 96-well plates.
In vitro cytotoxicity measurements
Different cell lines growing in 24- or 96-well 
plates were incubated with serial dilutions of Free-DOX, 
PEGylated liposomal DOX with or without ceramide 
alone or in combination, at fixed molar ratios, for 24, 
48 or 72 h at 37 °C in an atmosphere of 5% CO2. The 
toxicity was assessed either by the commonly used MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell viability test (Section 2.5.1) or by 
quantifying [3H]thymidine incorporation as a measure for 
cell proliferation (Section 2.5.2).
MTT cell viability assay
Briefly, after end of incubation, the cell medium 
was aspirated and exchanged with half the volume of 
medium containing a final concentration of 250 μg/mL 
MTT. The incubation was continued for 2 h at 37 °C for 
formation of the formazan-particles, which were dissolved 
in DMSO with 1% (v/v) NH4Cl. The absorbance was read 
in a plate reader (Biosys Ltd, Essex, UK) at 570 nm, and 
background from absorbance at 650 nm was subtracted.
Cell proliferation measured by [3H]thymidine 
incorporation
To measure DNA synthesis, the cell medium was 
aspirated, and substituted with serum free cell medium 
containing [3H]thymidine (3 μg/mL; 75 μCi/mL). The 
incubation was continued for 30 min at 37 °C. The 
medium was removed and 5% (w/v) TCA was added. 
After 5 min the cells were washed once with TCA and 
solubilised with 200 μL of 0.1 M KOH, before mixing 
with 3 mL scintillation fluid (Perkin Elmer, USA). The 
radioactivity was counted for 1 min in a scintillation 
counter (Tri-Carb 2100TR, Packard Bioscience, USA).
DOX cell extraction
The medium was removed from cells incubated with 
DOX or DOX-containing liposomes and the cells were 
then washed twice with PBS before lysis with 0.1% (v/v) 
Triton X-100, leaving the DOX-loaded liposomes intact. 
The liposome- and Free-DOX-containing lysates were 
mixed with 1:1 volume PBS (pH 7.4) and added to a SPE 
C18 SOLA column (Thermo Fisher Scientific #60109-
001) preconditioned by methanol and distilled water. The 
column containing the mixed lysate was washed once 
Oncotarget76932www.impactjournals.com/oncotarget
with PBS (pH 7.4) to allow liposomes to pass through 
the column bed. The column-bound DOX was eluted 
with methanol including 0.1% (v/v) TFA. The fraction 
containing liposomal DOX was treated with 1.5% (v/v) 
Triton X-100 in 5% (v/v) acetonitrile in water to disrupt 
liposomes and release DOX.
Western blotting
For immunoblotting of proteins 50,000 cells were 
incubated for 24 h and subjected to lysis in 50 μL lysis 
buffer (25 mM Tris·HCl pH 7.6, 150 mM NaCl, 1% 
(w/v) NP-40, 1% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 0.2% (w/v) octyl-β-D-glucopyranoside) on ice for 
10 min. The resulting protein lysate was mixed 1:1 with 
1.5% (w/v) SDS in lysis buffer and sonicated. SDS-PAGE 
separation was performed on a 4-20% TGX gel (Criterion, 
Bio-Rad, Oxford, UK) and proteins transferred onto a 0.2 
μm PVDF membrane with Transblot Turbo (Bio-Rad) 
system. Membranes were blocked with 5% (w/v) semi-
skimmed milk, incubated with primary antibodies at 4º C 
overnight, and probed with HRP-conjugated secondary 
antibodies. The protein bands were visualized by 
chemiluminescence and measured with Bio-Rad Quantity 
One on a Chemigenius system.
Animal studies
All procedures and experiments involving mice 
were approved by the National Animal Research Authority 
and were conducted according to the regulations of the 
Federation of European Laboratory Animal Science 
Association (FELASA). Mice were kept under pathogen-
free conditions, at constant temperature (21.5 ± 0.5°C) and 
humidity (55 ± 5%); 15 air changes/h and a 12 h light/dark 
cycle. Distilled water was given ad libitum, supplemented 
with 17-β-estradiol at a concentration of 4 mg/L. All mice 
used in the experiment were locally bred at the animal 
facility at Institute for Cancer Research, Oslo University 
Hospital [41].
The orthotopic basal-like xenograft mice model 
MAS98.12 has been established by directly grafting 
human primary breast cancer tissue and serially 
transplanted, as previously described [42]. For the study, 
1-2 mm3 pieces of MAS98.12 tumors were implanted 
bilaterally into the mammary fat pad of female athymic 
nude foxn1nu mice (age 6-7 weeks and body weights of 
15-20 g). After the tumors reached approximately 5 mm 
in diameter, the mice were randomly assigned to the 
different treatment groups (the average volume of each 
group was 24-30 mm3). The empty liposomes (Empty–
Lip-C6 and Empty–Lip-C12) were administered as a 
single intravenous tail vein injection with a dose of 6.5 
mg/kg ceramide and with additional 8 mg/kg doxorubicin 
in the drug loaded liposomes (DOX-Lip-C6 and DOX-
Lip-C12. Non-liposomal doxorubicin (Adriamycin®) 
and PEGylated liposomal doxorubicin (Caelyx®) were 
injected with 8 mg/kg body weight. Furthermore, saline 
was used as negative control. Tumor growth was measured 
twice per week, and tumor volumes were calculated using 
the formula length × width × width × 0.5.
CONCLUSION
We have shown that ceramide species with different 
chain lengths (C6 or C12) induce increased sensitivity 
of cancer cells to DOX in a cell-specific manner. 
Furthermore, we have also demonstrated the importance 
of investigating cell toxicity at different time points and 
with different cell-based assays to assess the efficacy of 
drug formulations in vitro. Longer incubation times were 
required to obtain cell toxicity with Caelyx®, the golden 
standard liposomal marketed product widely used for 
cancer therapy, compared to our liposomal formulations. 
Furthermore, our data show that the in vitro toxicity 
analyses of nanocarriers do not necessarily reflect their 







GCS - glucosylceramide synthase
LIP - liposomes
 MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny 
ltetrazolium bromide
PEG - polyethylene glycol 2000
Author contributions
AØ, AMH, MF, NS, TS performed the experiments; 
AØ, MF, TS, KS wrote the manuscript; all authors 
contributed with design and discussions.
ACKNOWLEDGMENTS
All groups were supported by the Research Council 
of Norway through its funding scheme NANO2021, 
project number 228200/O70 (Biodegradable nanoparticles 
in cancer diagnosis and therapy). The group working at 
the Department of Molecular Cell Biology was supported 
by The Norwegian Cancer Society, the Research Council 
of Norway through its Centre of Excellence funding 
scheme, project number 179571, and the South Eastern 
Norway Regional Health Authority. The group in Tromsø 
was supported by University of Tromsø The Arctic 
University of Norway, and the group at Department of 
Tumor Biology was supported by The Norwegian Cancer 
Society, project number 428152. We thank Anne Engen 
Oncotarget76933www.impactjournals.com/oncotarget
for excellent assistance with cell culturing. We are grateful 
for excellent technical help from Stein Waagene and Geir 
Frode Øy with animal studies. We would also like to thank 
The Simon Fougner Hartmann Family Fund for providing 




1. Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier 
potential of liposomes in cancer chemotherapy. Lancet. 
1974; 1:1313-1316.
2. Allen TM, Cullis PR. Liposomal drug delivery systems: 
from concept to clinical applications. Adv Drug Deliv Rev. 
2013; 65:36-48.
3. Mallick S, Choi JS. Liposomes: versatile and biocompatible 
nanovesicles for efficient biomolecules delivery. J Nanosci 
Nanotechnol. 2014; 14:755-765.
4. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine 
and tumor vascular permeability; Where is the missing link? 
J Control Release. 2012; 164:265-275.
5. Horowitz AT, Barenholz Y, Gabizon AA. In vitro 
cytotoxicity of liposome-encapsulated doxorubicin: 
dependence on liposome composition and drug release. 
Biochim Biophys Acta. 1992; 1109:203-209.
6. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren 
D. Liposome longevity and stability in circulation: effects 
on the in vivo delivery to tumors and therapeutic efficacy 
of encapsulated anthracyclines. J Drug Target. 1996; 
3:391-398.
7. Amantea M, Newman MS, Sullivan TM, Forrest A, 
Working PK. Relationship of dose intensity to the induction 
of palmar-plantar erythrodysesthia by pegylated liposomal 
doxorubicin in dogs. Hum Exp Toxicol. 1999; 18:17-26.
8. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, 
Kester M, McNeil SE. Rapid distribution of liposomal 
short-chain ceramide in vitro and in vivo. Drug Metab 
Dispos. 2008; 36:1709-1715.
9. Ruvolo PP. Intracellular signal transduction pathways 
activated by ceramide and its metabolites. Pharmacol Res. 
2003; 47:383-392.
10. Ogretmen B, Hannun YA. Biologically active sphingolipids 
in cancer pathogenesis and treatment. Nat Rev Cancer. 
2004; 4:604-616.
11. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi 
SA, Sentelle D, Selvam SP, Salas A, Ogretmen B. 
Sphingolipids and cancer: ceramide and sphingosine-1-
phosphate in the regulation of cell death and drug resistance. 
Future Oncol. 2010; 6:1603-1624.
12. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, 
Van Kaer L, Saiki I, Okumura K. Critical contribution 
of IFN-gamma and NK cells, but not perforin-
mediated cytotoxicity, to anti-metastatic effect of alpha-
galactosylceramide. Eur J Immunol. 2001; 31:1720-1727.
13. Maula T, Artetxe I, Grandell PM, Slotte JP. Importance of 
the sphingoid base length for the membrane properties of 
ceramides. Biophys J. 2012; 103:1870-1879.
14. Park WJ, Park JW. The effect of altered sphingolipid acyl 
chain length on various disease models. Biol Chem. 2015; 
396:693-705.
15. Su X, Song H, Niu F, Yang K, Kou G, Wang X, Chen 
H, Li W, Guo S, Li J, Li B, Feng SS, Jiang J, et al. 
Co-delivery of doxorubicin and PEGylated C16-ceramide 
by nanoliposomes for enhanced therapy against multidrug 
resistance. Nanomedicine (Lond). 2015; 10:2033-2050.
16. Watters RJ, Kester M, Tran MA, Loughran TP Jr, Liu X. 
Development and use of ceramide nanoliposomes in cancer. 
Methods Enzymol. 2012; 508:89-108.
17. Zhai L, Sun N, Han Z, Jin HC, Zhang B. Liposomal short-
chain C6 ceramide induces potent anti-osteosarcoma 
activity in vitro and in vivo. Biochem Biophys Res 
Commun. 2015; 468:274-280.
18. Pedrosa LR, van Hell A, Suss R, van Blitterswijk WJ, 
Seynhaeve AL, van Cappellen WA, Eggermont AM, ten 
Hagen TL, Verheij M, Koning GA. Improving intracellular 
doxorubicin delivery through nanoliposomes equipped with 
selective tumor cell membrane permeabilizing short-chain 
sphingolipids. Pharm Res. 2013; 30:1883-1895.
19. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update 
on anticancer molecular action, toxicity and novel drug 
delivery systems. J Pharm Pharmacol. 2013; 65:157-170.
20. Ji C, Yang B, Yang YL, He SH, Miao DS, He L, Bi ZG. 
Exogenous cell-permeable C6 ceramide sensitizes multiple 
cancer cell lines to Doxorubicin-induced apoptosis by 
promoting AMPK activation and mTORC1 inhibition. 
Oncogene. 2010; 29:6557-6568.
21. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, 
Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, 
Gouaze-Andersson V, Consoli DP, Cabot MC. A role for 
ceramide in driving cancer cell resistance to doxorubicin. 
FASEB J. 2008; 22:2541-2551.
22. Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, 
Ichikawa S, Hirabayashi Y, Holleran WM, Okazaki T. 
Ceramide reduction and transcriptional up-regulation of 
glucosylceramide synthase through doxorubicin-activated 
Sp1 in drug-resistant HL-60/ADR cells. Cancer Res. 2004; 
64:6271-6279.
23. Watters RJ, Fox TE, Tan SF, Shanmugavelandy S, Choby 
JE, Broeg K, Liao J, Kester M, Cabot MC, Loughran TP, 
Liu X. Targeting glucosylceramide synthase synergizes 
with C6-ceramide nanoliposomes to induce apoptosis 
in natural killer cell leukemia. Leuk Lymphoma. 2013; 
54:1288-1296.
24. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and 
nanoparticles to tumors. J Cell Biol. 2010; 188:759-768.
Oncotarget76934www.impactjournals.com/oncotarget
25. Fonseca NA, Gomes-da-Silva LC, Moura V, Simoes S, 
Moreira JN. Simultaneous active intracellular delivery 
of doxorubicin and C6-ceramide shifts the additive/
antagonistic drug interaction of non-encapsulated 
combination. J Control Release. 2014; 196:122-131.
26. Babiychuk EB, Atanassoff AP, Monastyrskaya K, 
Brandenberger C, Studer D, Allemann C, Draeger A. The 
targeting of plasmalemmal ceramide to mitochondria during 
apoptosis. PLoS One. 2011; 6:e23706.
27. Colombini M. Ceramide channels and their role in 
mitochondria-mediated apoptosis. Biochim Biophys Acta. 
2010; 1797:1239-1244.
28. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, 
Soto M, Perez JM. Poly(ADP-ribose) polymerase-1 (PARP-
1) inhibitors in cancer chemotherapy. Recent Pat Anticancer 
Drug Discov. 2006; 1:39-53.
29. Tran MA, Smith CD, Kester M, Robertson GP. Combining 
nanoliposomal ceramide with sorafenib synergistically 
inhibits melanoma and breast cancer cell survival to 
decrease tumor development. Clin Cancer Res. 2008; 
14:3571-3581.
30. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: 
a review of its use in metastatic breast cancer, ovarian 
cancer, multiple myeloma and AIDS-related Kaposi’s 
sarcoma. Drugs. 2011; 71:2531-2558.
31. Ong JC, Sun F, Chan E. Development of stealth liposome 
coencapsulating doxorubicin and fluoxetine. J Liposome 
Res. 2011; 21:261-271.
32. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. 
Modulation of intracellular ceramide using polymeric 
nanoparticles to overcome multidrug resistance in cancer. 
Cancer Res. 2007; 67:4843-4850.
33. Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, 
Fouque A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy 
A, Levade T, Theret N, et al. Downregulation of ceramide 
synthase-6 during epithelial-to-mesenchymal transition 
reduces plasma membrane fluidity and cancer cell motility. 
Oncogene. 2015; 34:996-1005.
34. Megha, Sawatzki P, Kolter T, Bittman R, London E. Effect 
of ceramide N-acyl chain and polar headgroup structure 
on the properties of ordered lipid domains (lipid rafts). 
Biochim Biophys Acta. 2007; 1768:2205-2212.
35. Morad SA, Levin JC, Shanmugavelandy SS, Kester M, 
Fabrias G, Bedia C, Cabot MC. Ceramide--antiestrogen 
nanoliposomal combinations--novel impact of hormonal 
therapy in hormone-insensitive breast cancer. Mol Cancer 
Ther. 2012; 11:2352-2361.
36. Stover TC, Sharma A, Robertson GP, Kester M. Systemic 
delivery of liposomal short-chain ceramide limits solid 
tumor growth in murine models of breast adenocarcinoma. 
Clin Cancer Res. 2005; 11:3465-3474.
37. Shabbits JA, Mayer LD. High ceramide content liposomes 
with in vivo antitumor activity. Anticancer Res. 2003; 
23:3663-3669.
38. van Lummel M, van Blitterswijk WJ, Vink SR, Veldman 
RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont 
AM, ten Hagen TL, Verheij M, Koning GA. Enriching lipid 
nanovesicles with short-chain glucosylceramide improves 
doxorubicin delivery and efficacy in solid tumors. FASEB 
J. 2011; 25:280-289.
39. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane 
ammonium sulfate gradients in liposomes produce efficient 
and stable entrapment of amphipathic weak bases. Biochim 
Biophys Acta. 1993; 1151:201-215.
40. Joraholmen MW, Vanic Z, Tho I, Skalko-Basnet N. 
Chitosan-coated liposomes for topical vaginal therapy: 
assuring localized drug effect. Int J Pharm. 2014; 
472:94-101.
41. Lindholm EM, Kristian A, Nalwoga H, Kruger K, Nygard 
S, Akslen LA, Maelandsmo GM, Engebraaten O. Effect of 
antiangiogenic therapy on tumor growth, vasculature and 
kinase activity in basal- and luminal-like breast cancer 
xenografts. Mol Oncol. 2012; 6:418-427.
42. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen 
H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, 
Fodstad O, Borresen-Dale AL, Engebraaten O. Molecular 
profiling and characterization of luminal-like and basal-like 
in vivo breast cancer xenograft models. Mol Oncol. 2009; 
3:469-482.
